The CCPG1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human cervical adenocarcinoma cell line, engineered for targeted disruption of the CCPG1 (Cell Cycle Progression Gene 1) locus. This loss-of-function model consists of a heterogeneous pool of cells carrying diverse editing events, enabling functional interrogation of CCPG1 without clonal selection. The polyclonal format captures a broad range of genetic modifications, providing a robust system for studying CCPG1-dependent phenotypes while mitigating clonal artifacts.
The parental HeLa cell line is an immortalized epithelial model originating from a cervical adenocarcinoma, notable for its integration of human papillomavirus type 18 (HPV-18) and consequent inactivation of the tumor suppressor p53 via the viral E6 oncoprotein. This p53 deficiency abrogates canonical p53-mediated cell cycle arrest and apoptosis, making HeLa cells a distinctive platform for exploring p53-independent or residual p53-pathway functions. The line??s vigorous proliferation, ease of genetic manipulation, and extensive characterization render it a standard for CRISPR-based gene editing in cancer research.
CCPG1 is a multifunctional protein positioned at the convergence of cell cycle control and apoptotic signaling. It physically interacts with TP53 and CDK2, and associates with Cyclin E, acting downstream of E2F transcription factors to promote the expression of Cyclin D1 and CDK4. Within the representative pathway TP53?CCCPG1?Cp21/CDKN1A?CCyclin D1?CCDK4?CRB1?CE2F1?CBAX?CCaspase-3, CCPG1 transduces signals that modulate G1/S transition and mitochondrial apoptosis. Disruption of CCPG1 by CRISPR/Cas9 eliminates these regulatory inputs, potentially uncoupling E2F-driven proliferation from survival controls, even in the absence of functional p53.
In the HeLa context, where p53 is constitutively degraded by HPV E6, CCPG1 knockout offers a unique opportunity to dissect p53-independent functions of this protein. While p53-mediated checkpoints are largely disabled, CCPG1 may sustain a parallel or alternative axis influencing cell cycle progression and apoptotic thresholds. Loss of CCPG1 in this background could exacerbate oncogenic traits or uncover synthetic vulnerabilities, particularly relevant to HPV-driven cervical carcinoma. This model thus facilitates the study of tumor cell adaptations and the identification of context-specific dependencies.
Researchers can employ this polyclonal knockout population in a variety of assays including Western blotting and RT-qPCR for validation of gene disruption, flow cytometry to assess cell cycle distribution, Annexin V staining for apoptosis quantification, MTT or similar proliferation assays, and co-immunoprecipitation to map CCPG1 protein interactions under native conditions. Applications extend to functional genomics screens, drug sensitivity profiling, and mechanistic studies of cervical cancer biology. For inquiries, please contact Ascent Research.
